That’s why plasma donors are heroes to millions of patients who receive plasma-derived therapies.
October 7, 2016 By Daniel Ferris
Immune deficiency patient Barb Roberts with Rusty Roberts vacationing in Dinard, France.
Every autumn the plasma protein therapeutics industry recognizes the lifesaving contributions of plasma donors during International Plasma Awareness Week (IPAW).
At CSL Behring and CSL Plasma, we appreciate the critical role donors play in ensuring a reliable and secure source of human plasma as worldwide demand continues to rise. We value their donations not just during IPAW (October 9-15), but year-round.
This is because plasma-derived therapies are crucial for patients’ well-being and health, and an appropriate supply of products is absolutely essential and depends on a sufficient supply of collected plasma.
While it can take more than 1,000 plasma donations to treat one adult patient for a year, the current collection system allows for an appropriate supply of product. Continue reading →
That’s why we’re building for the future in Lengnau and around the world to meet growing demand and bring more therapies to more patients.
September 22, 2016 By Uwe E. Jocham
These are exciting times at CSL Behring, as we expand our infrastructure to keep pace with the increasing demand for new innovations that address unmet medical needs or enhance current treatments.
We are currently building for the future in Lengnau, Switzerland, where we are constructing a state-of-the-art recombinant manufacturing facility. The foundation stone of the new structure was laid in May. With this production site, CSL Behring is creating a new product family based on state-of-the-art technology.
The plant will manufacture and globally market three new recombinant coagulation factors: recombinant Factor IX Fusion Protein for patients with hemophilia B, recombinant Factor VIII-Single Chain to treat hemophilia A, and a recombinant Factor VIIa-Fusion Protein treat hemophilia patients with inhibitors. Continue reading →
CSL Behring’s Bob Repella joined NORD’s Pam Gavin for a wide-ranging discussion about rare diseases at the 2016 BIO International Convention. The following is excerpted from his remarks.
By Bob Repella
Rare diseases are serious and often debilitating conditions that have a tremendous impact on 350 million patients worldwide, about half of whom are children, and their families. Today we are on the brink of significantly improving their lives through rare disease awareness, early diagnosis and innovative treatments.
More therapies are available today for previously unmet needs, and there are greater choices for patients than ever before. But even with this progress, a great deal of work remains to be done. Over 90% of the approximately 7,000 rare diseases have no treatment available, and there are still challenges to accessing existing therapies. Nevertheless, the trends overall are positive.
Hereditary Angioedema patients are a global family tied together by the need to reduce the time it takes to diagnose and treat this rare disease.
By Henrik Balle Boysen
Hereditary Angioedema International (HAEi) is a non-profit global network of national hereditary angioedema (HAE) patient associations for C1-Inhibitor deficiencies. We are dedicated to raising awareness of HAE and the people it affects around the world.
We strive to improve the time it takes to diagnose HAE and facilitate access to and reimbursement for life saving HAE therapies, which will enable lifelong health for all patients no matter where they live.
Anyone coping with a rare disease knows firsthand how difficult and frustrating it can be to find the correct diagnosis and proper treatment.
February 3, 2016
At CSL Behring, we understand the unique challenges faced by people stricken with life-threatening medical conditions because of our long experience, deep knowledge and unwavering focus on preventing and treating serious diseases.
Using the latest technologies, we are unlocking the potential of biotherapies to save lives and to help improve the quality of life of people living with rare and serious medical conditions. Our operational excellence combined with our focused global R&D organization enables us to efficiently identify, develop and deliver innovations that patients need and want.
We’ve never been more excited about emerging new medicines and technologies that hold the key to unprecedented opportunities to improve patient well-being. But the reality is that it can still take years just to obtain an accurate diagnosis.
The good news is that when the search is over, many people like Alice can – and do – lead active, fulfilling lives. This is her story.
Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring. This site is not intended as a forum for discussing CSL Behring or other companies' products. Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.